Park KT - Search Results

1

Appropriateness of emergency department use in pediatric inflammatory bowel disease: a quality improvement opportunity.

Hoffenberg EJ, Park KT, Dykes DM, Fridge J, Kappelman MD, Leibowitz IH, Tsou VM, Colletti RB. Hoffenberg EJ, et al. Among authors: park kt. J Pediatr Gastroenterol Nutr. 2014 Sep;59(3):324-6. doi: 10.1097/MPG.0000000000000457. J Pediatr Gastroenterol Nutr. 2014. PMID: 24918980 Free PMC article.

2

Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.

Park KT, Bass D. Park KT, et al. Inflamm Bowel Dis. 2011 Jul;17(7):1603-9. doi: 10.1002/ibd.21488. Epub 2010 Nov 4. Inflamm Bowel Dis. 2011. PMID: 21053357 Review.

3

Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.

Park KT, Perez F, Tsai R, Honkanen A, Bass D, Garber A. Park KT, et al. J Pediatr Gastroenterol Nutr. 2011 Nov;53(5):489-96. doi: 10.1097/MPG.0b013e3182293a5e. J Pediatr Gastroenterol Nutr. 2011. PMID: 21694634 Review.

4

Perspectives on cost-effective medicine and the use of cost-effectiveness analyses.

Park KT. Park KT. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):2-3. doi: 10.1097/MPG.0b013e3182354d50. J Pediatr Gastroenterol Nutr. 2012. PMID: 22197853 No abstract available.

5

Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.

Wu M, Sin A, Nishioka F, Park KT. Wu M, et al. Among authors: park kt. Inflamm Bowel Dis. 2013 Jun;19(7):1514-7. doi: 10.1097/MIB.0b013e318281f4f1. Inflamm Bowel Dis. 2013. PMID: 23567783 Free PMC article.

6

Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease.

Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ, Kappelman MD, Colletti RB. Park KT, et al. Inflamm Bowel Dis. 2014 May;20(5):946-51. doi: 10.1097/01.MIB.0000441349.40193.aa. Inflamm Bowel Dis. 2014. PMID: 24451222 Free PMC article. Review.

7

Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.

Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Park KT, et al. Inflamm Bowel Dis. 2014 Jul;20(7):1242-9. doi: 10.1097/MIB.0000000000000061. Inflamm Bowel Dis. 2014. PMID: 24846718 Free PMC article.

8

Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.

Sin AT, Damman JL, Ziring DA, Gleghorn EE, Garcia-Careaga MG, Gugig RR, Hunter AK, Burgis JC, Bass DM, Park KT. Sin AT, et al. Among authors: park kt. Inflamm Bowel Dis. 2015 Jun;21(6):1368-77. doi: 10.1097/MIB.0000000000000374. Inflamm Bowel Dis. 2015. PMID: 25839776 Free PMC article.

9

Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.

Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Park KT, et al. Am J Gastroenterol. 2016 Jan;111(1):15-23. doi: 10.1038/ajg.2015.207. Epub 2015 Jul 21. Am J Gastroenterol. 2016. PMID: 26195179

10

Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.

Frymoyer A, Piester TL, Park KT. Frymoyer A, et al. Among authors: park kt. J Pediatr Gastroenterol Nutr. 2016 May;62(5):723-7. doi: 10.1097/MPG.0000000000001123. J Pediatr Gastroenterol Nutr. 2016. PMID: 26890885 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

460 results

Search Page

Filters